Shopping Cart
- Remove All
- Your shopping cart is currently empty
FIDAS-3, a stilbene derivative and potent Wnt inhibitor with an IC50 of 4.9 μM for methionine S-adenosyltransferase 2A (MAT2A), exhibits anticancer activities by effectively competing with S-adenosylmethionine (SAM) for MAT2A binding.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $44 | In Stock | |
10 mg | $71 | In Stock | |
25 mg | $136 | In Stock | |
50 mg | $203 | In Stock | |
100 mg | $293 | In Stock | |
200 mg | $393 | In Stock | |
1 mL x 10 mM (in DMSO) | $43 | In Stock |
Description | FIDAS-3, a stilbene derivative and potent Wnt inhibitor with an IC50 of 4.9 μM for methionine S-adenosyltransferase 2A (MAT2A), exhibits anticancer activities by effectively competing with S-adenosylmethionine (SAM) for MAT2A binding. |
Targets&IC50 | Mat2A:4.9 μM |
In vitro | FIDAS-3 induces the expression of cell cycle inhibitor, p21WAF1/CIP1. FIDAS-3 (10 μM; 36 h) treatment reduces the levels of both S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) in LS174T cells.FIDAS-3 (3 μM; 7 days; LS174T cells) treatment significantly inhibits the proliferation of LS174T cells. FIDAS-3 (3-10 μM) treatment inhibits the expression of c-Myc and cyclinD1 in LS174T CRC cells. |
In vivo | FIDAS-3 (20 mg/kg;intraperitoneal injection;daily;for one months;C57BL/6J athymic nude mice) treatment significantly inhibits the growth of xenograft tumors. |
Molecular Weight | 259.29 |
Formula | C16H15F2N |
Cas No. | 1266684-01-8 |
Smiles | CN(C)c1ccc(\C=C\c2c(F)cccc2F)cc1 |
Relative Density. | 1.183 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 90 mg/mL (347.10 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.